Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis

Takayasu's Arteritis Clinical Trial

Official title:

Anti-tumor Necrosis Factor Therapy Effect on Takayasu Arteritis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02457585
• Other study ID #: 1312-079-541
• Status: Recruiting
• Phase: Phase 2
• First received: May 18, 2015
• Last updated: May 12, 2017
• Start date: March 2015
• Est. completion date: April 2018

Study information

• Verified date: March 2017
• Source: Seoul National University Hospital
• Contact: Sang Jin Lee, MD
• Phone: 82-10-8623-2648
• Email: dream1331[@]naver.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Clinical study of anti-tumor necrosis factor therapy in patients with Takayasu arteritis.

This study is single arm (anti Tumor necrosis factor therapy only) clinical trial. Enrolled patients will be 11

Description:

Clinical study of anti-tumor necrosis factor therapy in patients with Takayasu arteritis.

This study is single arm (anti Tumor necrosis factor therapy only) clinical trial. Enrolled patients will be 11 patients with active takayasu's arteritis

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 11
• Est. completion date: April 2018
• Est. primary completion date: August 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• active takayasu's arteritis

Exclusion Criteria:

• active Tuberculosis

• Liver function abnormality

• heart failure ( New York Heart Association III - IV)

• patients were not consented

Related Conditions & MeSH terms

• Arteritis
• Necrosis
• Takayasu Arteritis
• Takayasu's Arteritis

Intervention

Drug:
• remicade (anti tumor necrosis factor inhibitor)
single arm:remicade treatment group

Locations

Country	Name	City	State
Korea, Republic of	Seoul National University Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	remission induction at 30 weeks		30 weeks